$0.69
0.18%
Downside
Day's Volatility :14.24%
Upside
14.08%
20.29%
Downside
52 Weeks Volatility :81.36%
Upside
76.61%
Period | Petvivo Holdings Inc | Index (Russel 2000) |
---|---|---|
3 Months | 1.76% | 0.0% |
6 Months | -38.22% | 0.0% |
1 Year | -64.7% | 0.0% |
3 Years | -79.65% | -22.3% |
Market Capitalization | 13.8M |
Book Value | $0.04 |
Earnings Per Share (EPS) | -0.64 |
PEG Ratio | 0.0 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1652.05% |
Return On Assets TTM | -203.99% |
Return On Equity TTM | -1646.73% |
Revenue TTM | 975.3K |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | 5.6000000000000005% |
Gross Profit TTM | -85.6K |
EBITDA | -9.6M |
Diluted Eps TTM | -0.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 914.49%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.1K | ↑ 0.0% |
Net Income | -15.5M | ↑ 0.0% |
Net Profit Margin | -218.0K% | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 77.9K | ↑ 993.99% |
Net Income | -4.8M | ↓ 69.37% |
Net Profit Margin | -6.1K% | ↑ 211912.33% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.6K | ↓ 95.4% |
Net Income | -2.1M | ↓ 55.55% |
Net Profit Margin | -58.9K% | ↓ 52839.53% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.6K | ↑ 250.56% |
Net Income | -3.8M | ↑ 77.38% |
Net Profit Margin | -29.8K% | ↑ 29119.34% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 115.6K | ↑ 818.95% |
Net Income | -4.9M | ↑ 31.73% |
Net Profit Margin | -4.3K% | ↑ 25549.47% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 917.2K | ↑ 693.49% |
Net Income | -8.7M | ↑ 76.09% |
Net Profit Margin | -948.77% | ↑ 3326.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 223.3K | ↑ 283.81% |
Net Income | -2.1M | ↑ 6.7% |
Net Profit Margin | -938.57% | ↑ 2437.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 510.1K | ↑ 128.46% |
Net Income | -2.3M | ↑ 9.96% |
Net Profit Margin | -451.75% | ↑ 486.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 125.6K | ↓ 75.38% |
Net Income | -2.3M | ↑ 1.07% |
Net Profit Margin | -1.9K% | ↓ 1402.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 117.2K | ↓ 6.7% |
Net Income | -2.9M | ↑ 24.24% |
Net Profit Margin | -2.5K% | ↓ 614.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 207.4K | ↑ 76.96% |
Net Income | -3.7M | ↑ 26.53% |
Net Profit Margin | -1.8K% | ↑ 703.73% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 595.9K | ↑ 187.36% |
Net Income | -1.7M | ↓ 52.21% |
Net Profit Margin | -293.65% | ↑ 1471.9% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.9M | ↑ 0.0% |
Total Liabilities | 1.1M | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 691.1K | ↓ 63.56% |
Total Liabilities | 1.5M | ↑ 42.59% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 522.5K | ↓ 24.4% |
Total Liabilities | 1.6M | ↑ 1.48% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 835.2K | ↑ 59.85% |
Total Liabilities | 1.7M | ↑ 11.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 7.4M | ↑ 789.24% |
Total Liabilities | 1.4M | ↓ 16.83% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.4M | ↓ 67.16% |
Total Liabilities | 1.7M | ↑ 18.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 4.1M | ↓ 29.23% |
Total Liabilities | 1.5M | ↑ 1.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.6M | ↓ 36.6% |
Total Liabilities | 1.8M | ↑ 19.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.4M | ↓ 5.04% |
Total Liabilities | 1.7M | ↓ 3.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1M | ↑ 27.07% |
Total Liabilities | 2.7M | ↑ 57.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.1M | ↑ 31.06% |
Total Liabilities | 3.1M | ↑ 13.78% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.6M | ↓ 10.63% |
Total Liabilities | 2.7M | ↓ 11.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -143.0K | ↑ 0.0% |
Investing Cash Flow | -62.9K | ↑ 72.55% |
Financing Cash Flow | 204.7K | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -736.4K | ↑ 414.94% |
Investing Cash Flow | -103.8K | ↑ 64.99% |
Financing Cash Flow | 609.4K | ↑ 197.75% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -496.6K | ↓ 32.57% |
Investing Cash Flow | -65.2K | ↓ 37.19% |
Financing Cash Flow | 565.9K | ↓ 7.13% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.0M | ↑ 110.9% |
Investing Cash Flow | -160.2K | ↑ 145.67% |
Financing Cash Flow | 1.2M | ↑ 115.67% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.2M | ↑ 298.63% |
Investing Cash Flow | -183.2K | ↑ 14.37% |
Financing Cash Flow | 10.4M | ↑ 755.51% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↑ 62.74% |
Investing Cash Flow | -423.9K | ↑ 131.43% |
Financing Cash Flow | 1.6M | ↓ 84.8% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↑ 20.34% |
Investing Cash Flow | -58.7K | ↑ 135.65% |
Financing Cash Flow | 65.0K | ↓ 4257.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.8M | ↓ 14.51% |
Investing Cash Flow | -210.3K | ↑ 258.43% |
Financing Cash Flow | -1.6K | ↓ 102.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.3M | ↓ 26.07% |
Investing Cash Flow | -130.1K | ↓ 38.14% |
Financing Cash Flow | 1.5M | ↓ 94885.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.2M | ↑ 67.15% |
Investing Cash Flow | -47.4K | ↓ 63.57% |
Financing Cash Flow | 2.0M | ↑ 28.15% |
Sell
Neutral
Buy
Petvivo Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Petvivo Holdings Inc | 25.58% | -38.22% | -64.7% | -79.65% | -80.67% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Petvivo Holdings Inc | NA | NA | 0.0 | 0.0 | -16.47 | -2.04 | NA | 0.04 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Petvivo Holdings Inc | Buy | $17.3M | -80.67% | NA | 0.0% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Petvivo Holdings Inc
Revenue is up for the last 2 quarters, 48.26K → 123.75K (in $), with an average increase of 61.0% per quarter
Netprofit is up for the last 2 quarters, -2.65M → -2.04M (in $), with an average increase of 29.5% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 116.1%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 160.5%
Bard Associates Inc
Vanguard Group Inc
Geode Capital Management, LLC
State Street Corporation
Warberg Asset Management LLC
Regal Investment Advisors LLC
petvivo, inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. petvivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. petvivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. petvivo, inc, gel-del technologies, inc. and cosmetalife a corporation are all wholly-owned subsidiaries of petvivo holdings, inc.
Organization | Petvivo Holdings Inc |
Employees | 25 |
CEO | Mr. John Lai |
Industry | Information Technology Services |
A Spac I Acquisition Corp
$0.69
-10.02%
Keyarch Acquisition Corp
$0.69
-10.02%
Connexa Sports Technologies Inc
$0.69
-10.02%
Us Value Etf
$0.69
-10.02%
First Wave Biopharma Inc
$0.69
-10.02%
Global X Msci Next Emerging
$0.69
-10.02%
Fat Projects Acquisition Corp
$0.69
-10.02%
Capital Link Global Fintech
$0.69
-10.02%
Applied Uv Inc
$0.69
-10.02%